CIK 0001528115 · Non-accelerated filer<br>Smaller reporting company
Annexon, Inc.
Sign in to watch- Ticker
- ANNX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 275414423
- Phone
- (650) 822-5500
- Business address
- 1400 SIERRA POINT PARKWAY, BLDG C, SUITE 200, BRISBANE, CA, 94005
- Open-market buys, last 90 days
- $99,829
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$99,829. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-11 | Love Douglas President & CEO | Grant or award · Stock Option (Right to Buy) | +320,000 | 320,000 | ||
| 2022-02-11 | Overdorf Michael EVP & Chief Business Officer | Grant or award | +12,500 | 12,500 | ||
| 2022-02-11 | Overdorf Michael EVP & Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2022-02-11 | Keswani Sanjay EVP & Chief Medical Officer | Grant or award | +12,500 | 12,500 | ||
| 2022-02-11 | Keswani Sanjay EVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2022-02-11 | Lew Jennifer EVP & Chief Financial Officer | Grant or award | +12,500 | 14,500 | ||
| 2022-02-11 | Lew Jennifer EVP & Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2022-02-11 | Mattheakis Larry EVP & Chief Scientific Officer | Grant or award | +12,500 | 12,500 | ||
| 2022-02-11 | Mattheakis Larry EVP & Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2022-01-19 | Cockroft Bettina M. Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-11-11 | Love Douglas President & CEO | Option exercise | +70,942 | $1.41 | $100K | 70,942 |
| 2021-11-11 | Love Douglas President & CEO | Option exercise | +30,000 | $1.85 | $56K | 100,942 |
| 2021-11-11 | Love Douglas President & CEO | Option exercise · Stock Option (Right to Buy) | −70,942 | 0 | ||
| 2021-11-11 | Love Douglas President & CEO | Option exercise · Stock Option (Right to Buy) | −30,000 | 114,449 | ||
| 2021-09-30 | Mattheakis Larry Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +220,000 | 220,000 | ||
| 2021-09-16 | Love Douglas President & CEO | Option exercise | +7,500 | $1.41 | $11K | 7,500 |
| 2021-09-16 | Love Douglas President & CEO | Sale | −7,500 | $22.05 | $165K | 0 |
| 2021-09-16 | Love Douglas President & CEO | Option exercise · Stock Option (Right to Buy) | −7,500 | 37,994 | ||
| 2021-09-13 | Yednock Ted EVP & Chief Scientific Officer | Option exercise | +15,000 | $1.41 | $21K | 15,000 |
| 2021-09-13 | Yednock Ted EVP & Chief Scientific Officer | Option exercise | +1,190 | $5.11 | $6K | 16,190 |
Page 10 of 15 · 292 trades